Alkem Laboratories launches NeuCeno for adult partial seizures
In short
Alkem Laboratories has launched NeuCeno for adults with partial-onset seizures. The medicine is once a day and comes in five strengths. The report says studies showed fewer seizures in adults with uncontrolled focal seizures.
This matters for patients and doctors because it adds another treatment option. The report does not say the price, where it is sold, or how widely it will be used.
What the reporting says
Alkem Laboratories launched NeuCeno for partial-onset seizures in adults, according to the publisher summary. The once-daily oral therapy is available in five strengths, and clinical studies showed reductions in seizure frequency among adults with uncontrolled focal seizures. The immediate impact is a new treatment option, while the reporting does not state pricing, launch timing, or sales expectations.
Why it matters
Alkem Laboratories launched NeuCeno for adults with partial-onset seizures. The publisher summary says it is a once-daily oral therapy available in five strengths and that clinical studies showed reduced seizure frequency among adults with uncontrolled focal seizures. The report indicates a new treatment offering for patients and prescribers, but it does not provide pricing, approval details, or commercial expectations.